Atomo Diagnostics (ASX: AT1) (OTCPK: AMOSF) shares are up 140% today. The AT1 stock rise is closely linked to that of Lumos Diagnostics (ASX: LDX) (OTCPK: LDXHF) also up a further 140% today. We looked at Lumos and thought their 500% rise yesterday was excessive. Well, we're wrong so far even if we stand by the basic idea.
That idea about Lumos Diagnostics was that: “Our opinion, and it is merely opinion, is that the Lumos Diagnostics share price has got a bit ahead of itself here. Yes, FDA authorisation does normally mean a great deal to a pharma or medical testing company. But it's also usually the first authorisation received. So we'd expect LDX to possibly fade a bit as this all gets digested by the market. Yes, FDA approval is important, but 500% important for something already on sale to potentially half a billion people? We're unsure about that. “ Given that Lumos has doubled again since then clearly even if we're right about this we're not right yet. Timing being one of those important things in stock markets.
As to why we think this way, yes, FDA approval is vital to be able to sell in the US. But the same test is already available in Europe and, well across the rest of the rich world actually. So, how much extra is that American market?

Atomo Diagnostics share price from ASX
As to why Atomo is following Lumos up, there's this announcement: “It is noted however that on 3 July 2023, Atomo's partner, Lumos Diagnostics (ASX: LDX) announced to the market that it has received US FDA approval for its FebriDx test, which utilises Atomo's user friendly integrated Pascal test platform, making Atomo a critical supplier to Lumos for this approved product. It is possible that the price movement in AT1 could be attributed to LDX's announcement.” Other than that management don't know of any reason for the 140% rise in AT1 shares.
Having been wrong once already we're of course hesitant to be so again. But we do think that 1,000% (for Lumos) is a bit much, the announcement isn't that, that, exciting. It's also difficult to see what the revenue gain to Atomo is of the FDA approval. So, we'll retreat to hte idea that clearly there's something of a frenzy going on here. And frenzies do end and prices fall back when they do. But it's never really possible to determine when that's going to happen - nor what price will be reached before it does.
So the conclusion so far is that this is very definitely a situation to be traded, at best, it's most certainly not an investment. Any position here needs to be watched, closely.



